Oral Board Case: Esophageal Carcinoma

What is your differential and what features make esophageal cancer most likely here?

Expected answer

Progressive dysphagia (solids then liquids), weight loss, regurgitation, and anemia point strongly to a malignant esophageal obstruction. Differential includes esophageal carcinoma (adenocarcinoma vs squamous cell), peptic stricture, achalasia, and esophageal web/ring. This patient has risk factors for both histologies: smoking and alcohol favor squamous cell carcinoma, while his chronic GERD (and possible Barrett's) favors adenocarcinoma. The progressive nature and weight loss make a benign stricture less likely and mandate tissue diagnosis. Dysphagia and weight loss are typically late symptoms—roughly 50% of patients have unresectable or metastatic disease at diagnosis.

How will you work this patient up?

Expected answer

Upper endoscopy is the gold standard—it allows direct visualization, characterization of the lesion's size and location, and, most importantly, tissue biopsy for diagnosis. A barium swallow can demonstrate the classic 'apple core' lesion and functionally characterize the stricture. Once cancer is confirmed I would obtain baseline labs (CBC, chemistries, nutritional markers) and address the anemia.

Once carcinoma is confirmed, how do you stage this patient?

Expected answer

Staging determines resectability. CT of the chest and abdomen (with the neck as indicated) evaluates for metastatic disease to liver and lungs and local invasion. PET/CT improves detection of occult distant metastases. Endoscopic ultrasound (EUS) is essential for resectable disease—it defines T stage (depth of invasion) and assesses regional lymph node involvement with FNA. Adjuncts include bronchoscopy for upper/mid lesions to exclude airway invasion or fistula. TNM: Tis is high-grade dysplasia, T1 submucosa, T2 muscularis propria, T3 adventitia, T4 adjacent structures; N1 = 1–3 nodes, N2 = 4–6, N3 = ≥7.

The patient asks why nodal disease matters so much. What do you tell him?

Expected answer

Esophageal cancer spreads to nodes early and rapidly because of the rich submucosal lymphatic network. Even T1 (submucosal) lesions carry a 14–21% incidence of nodal metastases, and T2 lesions 38–60%. Nodal involvement upstages the patient and generally shifts management toward neoadjuvant therapy before any resection, since it significantly worsens prognosis. Overall 5-year survival is only 15–25%.

He has T3 disease with regional nodal involvement but no distant metastases. What is your treatment plan?

Expected answer

This is locally advanced but potentially resectable disease. The standard is neoadjuvant chemoradiation followed by esophagectomy in a good surgical candidate. Neoadjuvant therapy improves survival for resectable thoracic esophageal cancer and can downstage the tumor. I would restage after neoadjuvant therapy before proceeding to resection. In the interim I would optimize his nutrition given significant weight loss—via enteral access (jejunostomy preferred to preserve the stomach as a conduit) or an esophageal stent to bridge him through therapy.

How do you optimize this cachectic patient before surgery, and any pitfalls with feeding access?

Expected answer

Malnutrition increases anastomotic and pulmonary complications, so nutritional optimization is important. Options include a preoperative jejunostomy or an esophageal stent to allow oral/enteral intake during neoadjuvant therapy. I would avoid a gastrostomy when a gastric conduit reconstruction is planned, because it can compromise the stomach and its blood supply for the future esophagogastric anastomosis—a feeding jejunostomy is safer in that regard.

Compare the surgical approaches for esophagectomy. Which would you choose and why?

Expected answer

The main approaches are transhiatal, Ivor-Lewis (transthoracic, right thoracotomy + laparotomy with intrathoracic anastomosis), and the three-field/McKeown approach (abdomen, chest, and neck with cervical anastomosis). None has been shown to differ in survival benefit or operative mortality. The transhiatal approach is associated with lower postoperative morbidity and avoids a thoracotomy, but a cervical anastomotic leak is more common (though generally better tolerated than an intrathoracic leak). Choice depends on tumor location and surgeon experience; a mid/upper lesion or need for wide en bloc lymphadenectomy favors a transthoracic or three-field approach.

For which patients is surgery NOT the answer, and what are your palliative options?

Expected answer

Patients with unresectable disease—T4 invasion of unresectable adjacent structures, distant metastases, or those with prohibitive comorbidities—are not surgical candidates. Squamous cell carcinoma may respond completely to chemoradiation, which can be definitive. Palliative options for dysphagia and quality of life include chemoradiation, esophageal stenting, laser ablation, and feeding gastrostomy or jejunostomy for nutrition. The goal shifts to relief of obstruction and maintenance of nutrition.

You perform an Ivor-Lewis esophagectomy. On POD 5 he develops fever, tachycardia, and leukocytosis. What is your concern and management?

Expected answer

My leading concern is an anastomotic leak, which is a major cause of morbidity and mortality after esophagectomy. I would assess hemodynamics and resuscitate, obtain a CT with oral contrast (or contrast esophagram) and consider endoscopy to confirm and localize the leak. A contained, well-drained leak in a stable patient can often be managed non-operatively with NPO, broad-spectrum antibiotics, adequate drainage (existing or image-guided), and jejunostomy/enteral nutrition; endoscopic stenting or clipping may help. A large, uncontained intrathoracic leak with sepsis requires operative intervention—drainage, repair or diversion. I would also watch for conduit ischemia.